

Haematologica
HAEMATOL/2020/258426
Version 3

A deep molecular response of splenic marginal zone lymphoma to
front-line checkpoint blockade

Peter G. Miller, Adam S. Sperling, Christopher J. Gibson, Olga
Pozdnyakova, Waihay J. Wong, Michael P. Manos, Elizabeth I.
Buchbinder, F. Stephen Hodi, Benjamin L. Ebert, and Matthew S.
Davids

Disclosures: P.G.M. has received consulting fees from Foundation Medicine, Inc. B.L.E. has received research funding from Celgene. B.L.E. has received research funding from Deerfield, consulting fees from GRAIL, and is on the scientific advisory boards for Exo Therapeutics and Skyhawk Therapeutics. E.I.B. has received consulting fees from Novartis and Bristol Myers Squibb and clinical trial support from Merck and Bristol Myers Squibb. M.S.D. has received research funding from Astra-Zeneca, Bristol Myers Squibb, Genentech, MEI Pharma, Pharmacyclics, Surface Oncology, TG Therapeutics and Verastem, and consulting fees from AbbVie, Adaptive Biotechnologies, Ascentage Pharma, Astra-Zeneca, BeiGene, Celgene, Genentech, Gilead Sciences, Janssen, MEI Pharma, Merck, Pharmacyclics, Syros Pharmaceuticals, TG Therapeutics, Verastem, and Zentalis. F.S.H. has received research support from Novartis, consulting fees from Novartis, Genentech/Roche, Aduro, Sanofi, Kairos, and Pieris, sits on the advisory board for Takeda, Surface, Compass Therapeutic, Apricity, Pionyr, Verastem, Torque, Rheos, Bicara, and Amgen, and has equity in Apricity, Pionyr, Torque, and Kairos. Full ICMJE disclosure forms are available upon request.

Contributions: P.G.M., A.S.S., C.J.G., and M.S.D. designed and conceived the study. M.M., S.H., E.B., O.P. and W.W. collected the blood and bone marrow samples and processed the samples. P.G.M., A.S.S., C.J.G., and M.S.D. analyzed and interpreted the data. P.G.M., A.S.S. and M.S.D. drafted the manuscript. M.S.D. and B.L.E. obtained funding and supervised the study.